XM无法为美国居民提供服务。
R
R

Roche

市场新闻

Roche Holding Publishes Data Regarding Evrysdi Efficacy

BRIEF-Roche Holding Publishes Data Regarding Evrysdi Efficacy Oct 14 (Reuters) - ROCHE HOLDING AG ROG.S : POSITIVE DATA CONFIRM EVRYSDI EFFICACY AND SAFETY IN CHILDREN FIRST TREATED PRE-SYMPTOMATICALLY BEFORE 6 WEEKS OF AGE, WITH MOST ACHIEVING MOTOR MILESTONES SIMILAR TO CHILDREN WITHOUT SMA Source text for Eikon: ID:nBw92GX3Ja Further company cov
R

Roche Receives FDA Approval For Itovebi

BRIEF-Roche Receives FDA Approval For Itovebi Oct 11 (Reuters) - ROCHE HOLDING AG ROG.S : FDA APPROVES ROCHE’S ITOVEBI, A TARGETED TREATMENT FOR ADVANCED HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER WITH A PIK3CA MUTATION ROCHE HOLDING AG - ITOVEBI REGIMEN DOUBLES PROGRESSION-FREE SURVIVAL IN PHASE III STUDY ROCHE HOLDING AG - ITOVEBI R
R

FDA Approves Inavolisib With Palbociclib & Fulvestrant For Endocrine-Resistant,Pik3ca-Mutated,Hr-Positive,Her2-Negative,Advanced Breast Cancer

BRIEF-FDA Approves Inavolisib With Palbociclib & Fulvestrant For Endocrine-Resistant,Pik3ca-Mutated,Hr-Positive,Her2-Negative,Advanced Breast Cancer Oct 10 (Reuters) - FDA: FDA APPROVES INAVOLISIB WITH PALBOCICLIB AND FULVESTRANT FOR ENDOCRINE-RESISTANT, PIK3CA-MUTATED, HR-POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER FDA: APPROVED FOUNDATIONONE
R

Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study

BUZZ-Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study ** Shares of drug developer Tempest Therapeutics TPST.O up 19.21% at $1.60 premarket ** TPST to conduct a late-stage study of its experimental drug amezalpat, in combination with Swiss drugmaker Roche's ROG.S Tecentriq and bevacizumab, for the treatment of me
R

Roche Obtains CE Certification For Companion Diagnostic

BRIEF-Roche Obtains CE Certification For Companion Diagnostic Oct 10 (Reuters) - ROCHE HOLDING AG ROG.S : OBTAINS CE CERTIFICATION FOR THE FIRST COMPANION DIAGNOSTIC TO IDENTIFY PATIENTS WITH GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER ELIGIBLE FOR TARGETED TREATMENT WITH VYLOY Source text for Eikon: ID:nGNE1TDGf7 Further company coverage: ROG.S (
R

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明